At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 305 enrolled
Drug / intervention
Amlodipine +1 moredrug
Likely dose
Amlodipine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Comparative Study Between Amlodipine 5mg And 10mg In Patients With Essential Hypertension For Whom Amlodipine 5mg Is Insufficiently Effective
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Dec 25, 2006·Updated Feb 11, 2021
In Brief
A Phase 3 clinical trial evaluating Amlodipine for Hypertension. Completed, enrolled 305 participants across 14 sites.
Detailed Summary
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartJan 2007
Primary CompletionOct 2007
TodayJul 2026
First PostedDec 25, 2006
Enrollment StartJan 1, 2007
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.5 years ago
Interventions
Amlodipinedrug
Amlodipine 5mg/ day
Amlodipinedrug
Amlodipine 10mg/ day